Malfertheiner P
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guercke University of Magdeburg, Germany.
Eur J Gastroenterol Hepatol. 2001 Aug;13 Suppl 2:S9-11.
Several large studies investigating the benefit of eradicating Helicobacter pylori in patients with functional dyspepsia have reported varying results, and therefore questions about the clinical management of H. pylori infection remain. The ELAN study, a recent large multicentre, randomized study, compared eradication of H. pylori (with lansoprazole and antibiotics) with acid-suppressant treatment alone (lansoprazole) in H. pylori-associated functional dyspepsia. Investigators found that eradication led to improvement of dyspeptic symptoms. Although the symptomatic benefit was limited to a small subset of patients (approximately 9%) with H. pylori-positive functional dyspepsia, cure of chronic gastritis can be offered to the majority of patients (approximately 80%) and thus, in addition to the elimination of symptoms in some, the key risk factor for gastroduodenal pathology is eliminated. This study provides support for the recommendations of Maastricht 2, which found that H. pylori eradication is an appropriate therapeutic option for functional dyspepsia.
几项针对根除幽门螺杆菌对功能性消化不良患者益处的大型研究报告了不同的结果，因此关于幽门螺杆菌感染的临床管理问题仍然存在。ELAN研究是最近一项大型多中心随机研究，比较了在幽门螺杆菌相关性功能性消化不良中，根除幽门螺杆菌（使用兰索拉唑和抗生素）与单纯抑酸治疗（兰索拉唑）的效果。研究人员发现根除幽门螺杆菌可改善消化不良症状。虽然症状改善仅限于一小部分（约9%）幽门螺杆菌阳性功能性消化不良患者，但大多数患者（约80%）可治愈慢性胃炎，因此，除了使部分患者症状消除外，还消除了胃十二指肠病变的关键危险因素。这项研究为马斯特里赫特2的建议提供了支持，该建议发现根除幽门螺杆菌是功能性消化不良的一种合适治疗选择。
